Galderma Group AG: Dermatitis, Atopic trials

The registry lists 14 Dermatitis, Atopic studies with Galderma Group AG as lead sponsor. 2 are open to participants now and 10 have results posted.

Phase 2 7Phase 3 4Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic DermatitisRecruitingNCT07762833Phase 3
• Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & AdultsRecruitingNCT06988605
• Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT04921345Phase 2Results posted
• A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT04562116Phase 2Results posted
• A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With NemolizumabCompletedNCT04365387Phase 2Results posted
• Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic DermatitisCompletedNCT03989349Phase 3Results posted
• Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic DermatitisCompletedNCT03985943Phase 3Results posted
• A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)CompletedNCT03921411Phase 2Results posted
• Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic DermatitisCompletedNCT03250624Phase 2Results posted
• Dose-ranging Study of Nemolizumab in Atopic DermatitisCompletedNCT03100344Phase 2Results posted
• Cetaphil Restoraderm Effect on Young Children With Atopic DermatitisCompletedNCT02589392Not applicableResults posted
• Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic DermatitisCompletedNCT00919763Phase 2Results posted
• Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically AdvisableWithdrawnNCT05056779Phase 3
• Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids ApplicationCompletedNCT01063218Phase 4